EUCTR2011-003018-17-ES进行中（未招募）1 期
The SPD489-322 Phase 3, Multicenter, Randomized, Double-blind, Parallel-group, Placebo-controlled, Flexible Dose Titration, Efficacy and Safety Study of SPD489 in Combination with an Antidepressant in the Treatment of Adults with Major Depressive Disorder with Inadequate Response to Prospective Treatment with an Antidepressant - SPD489-322
适应症
相关药物
试验速览
- 阶段
- 1 期
- 状态
- 进行中（未招募）
- 入组人数
- 1,262
研究概览
简要总结
暂无简介。
研究设计
- 研究类型
- Interventional clinical trial of medicinal product
入排标准
- 性别
- All
入选标准
- •Subject has a primary diagnosis of non-psychotic major depressive disorder (single or recurrent) as defined by the Structured Clinical Interview for DSM-IV-TR disorders ? Axis-I (SCID-CT) that has lasted ?8 weeks prior to the Screening Visit (Visit 1).
- •Subject has a Montgomery Asburg Depression Rating Scale (MADRS) total score ?24 at the Lead-in Baseline Visit (Visit 2).
- •Are the trial subjects under 18? no
- •Number of subjects for this age range:
- •F.1.2 Adults (18-64 years) yes
- •F.1.2.1 Number of subjects for this age range 1012
- •F.1.3 Elderly (>=65 years) yes
- •F.1.3.1 Number of subjects for this age range 22
排除标准
- •Subject whose current episode of MDD has not responded to an adequate
- •treatment regimen (at least 6 weeks of treatment at the maximum
- •tolerated adult dose approved for the indication) with 2 or more
- •approved single antidepressant agents. Any subjects whose current
- •episode of MDD has not responded to an approved adjunctive treatment
- •strategy is to be excluded.
- •Subject who has a lifetime history of treatment-resistant depression,
- •defined as having not responded to adequate treatment (at least 8
- •weeks at the maximum tolerated adult dose approved for the indication)
- •with 2 or more treatment regimens, including, distinct classes of
- •approved single antidepressant agents and adjunctive treatment
- •Subject is considered a suicide risk in the opinion of the Investigator,
- •has previously made a suicide attempt within the past 3 years, or is
- •currently demonstrating active suicidal ideation.
- •Subject has any current co-morbid psychiatric disorder that is either
- •controlled with medications prohibited in this study or is uncontrolled
- •and associated with significant symptoms. Excluded are: any significant
- •Axis II disorders, any bipolar disorder, any current or lifetime psychosis,
- •post-traumatic stress disorder, anorexia nervosa, and blumia nervosa. A
- •history of serious cardiac problems that may place them at increased
- •vulnerability to the sympathomimetic effects of a stimulant medication,
- •a history of moderate to severe hypertension or an average (of 3
- •readings) resting sitting systolic blood pressure >139mmHg or an
- •average (of 3 readings) diastolic blood pressure >89mmHg the
- •Screening Visit (Visit 1) and/or Lead-in Baseline Visit (Visit 2), or a
- •concurrent chronic or acute illness or unstable medical condition that
- •may deteriorate that could confound the results of safety assessments,
- •increase risk to the subject, or lead to difficulty complying with the
研究者
相似试验
进行中（未招募）
3 期
Placebo Controlled, Parallel-Group Study of SJP-0132 in Patients with Dry Eye DiseaseDry Eye DiseaseJPRN-jRCT2031220497Omatsu Kazunori498
进行中（未招募）
不适用
A multicenter, Randomized, Double-Bind, Phase 3 Study of Ramucirumab (IMC-1121B) Drug Product and Best Supportive Care (BSC) Versus Placebo and BSC as Second-Line Treatment in Patients With Hepatocellular Carcinoma Following First-Line Therapy With Sorafenib - NDHepatocellular CarcinomaEUCTR2010-019318-26-ITIMCLONE LLC544
进行中（未招募）
1 期
A Phase 2/3 Study in Adult and Pediatric Participants with SCDSickle Cell DiseaseCTIS2023-508766-14-00Global Blood Therapeutics Inc.229
已完成
3 期
MKK4482-013: MK-4482 Phase 3 Study for Prevention of COVID-19 in AdultsPACTR202203593113347MSD Pty Ltd150
进行中（未招募）
1 期
Study to evaluate the safety and efficacy of nivolumab combined with ipilimumab as first-line (1L) therapy for participants with advanced HCC.Hepatocellular Carcinoma, Hepatocellular Carcinoma, Hepatocellular Carcinoma, Hepatocellular CarcinomaMedDRA version: 21.1Level: LLTClassification code: 10049010Term: Carcinoma hepatocellular Class: 10029104MedDRA version: 20.0Level: PTClassification code: 10073071Term: Hepatocellular carcinoma Class: 100000004864CTIS2023-508635-31-00Bristol Myers Squibb International Corporation763